Related Experiment Video
Updated: Mar 28, 2026
A Novel Stromal Fibroblast-Modulated 3D Tumor Spheroid Model for Studying Tumor-Stroma Interaction and Drug Discovery
Published on: February 28, 2020
FHL2: a scaffold protein of carcinogenesis, tumour-stroma interactions and treatment response
Laurine Verset1, Lynn Feys2, Anne-Laure Trépant1
1Department of Pathology, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
Abstract:
Four-and-a-half LIM-domain protein 2 (FHL2) is a multifunctional scaffolding protein regulating signalling cascades and gene transcription. It shuttles between focal adhesions and the nucleus where it signals through direct interaction with a number of proteins including β-catenin. The multiplicity of molecular pathways affected by FHL2 suggests an important role in several physiological and pathological events. The function of FHL2 in cancer is particularly intriguing, since it may act as an oncoprotein or as a tumour suppressor in a tissue-dependent fashion. In this review we present the current knowledge on the role of FHL2 in carcinogenesis, with emphasis on the digestive tract. We discuss the overexpression of FHL2 in colorectal, gastric and pancreatic cancer, the downregulation in hepatocellular carcinoma and the role of FHL2 in epithelial-mesenchymal transition. We briefly look at the potential role of FHL2 in the tumoural microenvironment and discuss how FHL2 expression and function might influence cancer treatment. Before implementation of FHL2 as a biomarker by pathologists, antibody validation should, however, be carried out.
Insights
Four-and-a-half LIM-domain protein 2 (FHL2) impacts cancer development, acting as an oncoprotein or tumor suppressor. Its role in digestive tract cancers, like colorectal and gastric, warrants further investigation for potential therapeutic strategies.
Area of Science:
- Molecular Biology
- Oncology
- Biochemistry
Background:
- Four-and-a-half LIM-domain protein 2 (FHL2) is a key scaffolding protein involved in cell signaling and gene transcription.
- FHL2's dual role in cancer, potentially acting as an oncoprotein or tumor suppressor depending on the tissue, highlights its complex involvement in carcinogenesis.
- Its shuttling between focal adhesions and the nucleus, interacting with proteins like β-catenin, underscores its regulatory functions in cellular processes.
Purpose of the Study:
- To review the current understanding of FHL2's role in cancer development, focusing on the digestive tract.
- To explore FHL2's differential expression in various digestive cancers and its involvement in epithelial-mesenchymal transition.
- To discuss FHL2's potential impact on the tumor microenvironment, cancer treatment, and its utility as a diagnostic biomarker.
Main Methods:
- Literature review synthesizing existing research on FHL2 in carcinogenesis.
- Analysis of FHL2 expression patterns in colorectal, gastric, pancreatic, and hepatocellular carcinoma.
- Discussion of FHL2's involvement in epithelial-mesenchymal transition and the tumor microenvironment.
Main Results:
- FHL2 is overexpressed in colorectal, gastric, and pancreatic cancers, suggesting an oncogenic role.
- Conversely, FHL2 is downregulated in hepatocellular carcinoma, indicating a potential tumor-suppressive function in this context.
- FHL2 plays a role in epithelial-mesenchymal transition, a process critical for cancer metastasis.
Conclusions:
- FHL2 exhibits context-dependent roles in digestive tract cancers, acting as either an oncoprotein or tumor suppressor.
- Further research into FHL2's function in the tumor microenvironment and its influence on treatment response is warranted.
- Robust antibody validation is essential before FHL2 can be reliably implemented as a pathological biomarker.
